IMMIX BIOPHARMA, INC. Research and Development Expense
IMMIX BIOPHARMA, INC. (IMMX) reported Research and Development Expense of $5.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. research and development expense for the quarter ending 2026-06-30 was $5.33M, a 34.25% increase year-over-year.
- IMMIX BIOPHARMA, INC. research and development expense for the quarter ending 2026-03-31 was $5.98M, a 202.80% increase year-over-year.
- IMMIX BIOPHARMA, INC. research and development expense for the quarter ending 2025-12-31 was $5.73M, a 316.70% increase year-over-year.
- IMMIX BIOPHARMA, INC. research and development expense for the quarter ending 2025-09-30 was $4.58M, a 3.12% increase year-over-year.
- IMMIX BIOPHARMA, INC. research and development expense for fiscal 2025 was $16.26M, a 43.97% increase from fiscal 2024.
- IMMIX BIOPHARMA, INC. research and development expense for fiscal 2024 was $11.29M, a 29.28% increase from fiscal 2023.
- IMMIX BIOPHARMA, INC. research and development expense for fiscal 2023 was $8.74M, a 108.19% increase from fiscal 2022.
- IMMIX BIOPHARMA, INC. research and development expense for fiscal 2022 was $4.20M, a 3216.11% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.33M 10-Q · filed 2026-08-07 | $11.31M 10-Q · filed 2026-08-07 | $17.04M derived: sum of 3 quarters · filed 2026-08-07 | $21.62M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $5.98M 10-Q · filed 2026-05-07 | $11.71M derived: sum of 2 quarters · filed 2026-05-07 | $16.29M derived: sum of 3 quarters · filed 2026-05-07 | $20.26M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $5.73M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | $10.31M derived: sum of 2 quarters · filed 2026-03-27 | $14.28M derived: sum of 3 quarters · filed 2026-08-07 | $16.26M 10-K/A · filed 2026-03-27 |
| 2025-09-30 | $4.58M 10-Q · filed 2025-11-07 | $8.56M derived: sum of 2 quarters · filed 2026-08-07 | $10.53M 10-Q · filed 2025-11-07 | $11.91M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $3.97M 10-Q · filed 2026-08-07 | $5.95M 10-Q · filed 2026-08-07 | $7.32M derived: sum of 3 quarters · filed 2026-08-07 | $11.77M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.98M 10-Q · filed 2026-05-07 | $3.35M derived: sum of 2 quarters · filed 2026-05-07 | $7.79M derived: sum of 3 quarters · filed 2026-05-07 | $10.02M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.37M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | $5.82M derived: sum of 2 quarters · filed 2026-03-27 | $8.04M derived: sum of 3 quarters · filed 2026-03-27 | $11.29M 10-K/A · filed 2026-03-27 |
| 2024-09-30 | $4.45M 10-Q · filed 2025-11-07 | $6.67M derived: sum of 2 quarters · filed 2025-11-07 | $9.92M 10-Q · filed 2025-11-07 | $13.02M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $2.22M 10-Q · filed 2025-08-08 | $5.47M 10-Q · filed 2025-08-08 | $8.57M derived: sum of 3 quarters · filed 2025-08-08 | $10.68M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $3.25M 10-Q · filed 2025-05-08 | $6.35M derived: sum of 2 quarters · filed 2025-05-08 | $8.46M derived: sum of 3 quarters · filed 2025-05-08 | $10.66M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $5.21M derived: sum of 2 quarters · filed 2025-03-25 | $7.42M derived: sum of 3 quarters · filed 2025-03-25 | $8.74M 10-K · filed 2025-03-25 |
| 2023-09-30 | $2.11M 10-Q · filed 2024-11-12 | $4.32M derived: sum of 2 quarters · filed 2024-11-12 | $5.63M 10-Q · filed 2024-11-12 | $7.90M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $2.21M 10-Q · filed 2024-08-12 | $3.53M 10-Q · filed 2024-08-12 | $5.79M derived: sum of 3 quarters · filed 2024-08-12 | $6.49M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $1.32M 10-Q · filed 2024-05-09 | $3.58M derived: sum of 2 quarters · filed 2024-05-09 | $4.28M derived: sum of 3 quarters · filed 2024-05-09 | $4.89M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $2.96M derived: sum of 2 quarters · filed 2024-03-29 | $3.57M derived: sum of 3 quarters · filed 2024-03-29 | $4.20M 10-K · filed 2024-03-29 |
| 2022-09-30 | $695.94K 10-Q · filed 2023-11-13 | $1.30M derived: sum of 2 quarters · filed 2023-11-13 | $1.93M 10-Q · filed 2023-11-13 | $1.94M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $607.75K 10-Q · filed 2023-08-11 | $1.24M 10-Q · filed 2023-08-11 | $1.25M derived: sum of 3 quarters · filed 2023-08-11 | $1.28M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $629.53K 10-Q · filed 2023-05-12 | $638.77K derived: sum of 2 quarters · filed 2023-05-12 | $668.46K derived: sum of 3 quarters · filed 2023-05-12 | $731.22K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $9.24K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $38.93K derived: sum of 2 quarters · filed 2023-03-27 | $101.69K derived: sum of 3 quarters · filed 2023-03-27 | $126.53K 10-K · filed 2023-03-27 |
| 2021-09-30 | $29.69K 10-Q · filed 2022-11-09 | $92.45K derived: sum of 2 quarters · filed 2022-11-09 | $117.29K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $62.76K 10-Q · filed 2022-08-12 | $87.60K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $24.84K 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $248.15K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |